NDATOPICALGEL
Approved
Jun 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
3/8 — Basic
TAZORAC (tazarotene) by Almirall. Approved for retinoid [epc]. First approved in 1997.
Drug data last refreshed 21h ago · AI intelligence enriched 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TAZORAC (tazarotene) is a topical retinoid gel approved in 1997 for treating acne and psoriasis. It works by binding to retinoic acid receptors (RARα, RARβ, RARγ) with selectivity for RARβ and RARγ, modulating gene expression to reduce comedone formation and promote cell turnover. The drug is administered topically as a gel formulation.
LOE Approaching
Aging franchise with LOE approaching signals defensive commercial strategy and reduced headcount expansion; teams focus on maximizing existing patient base rather than growth initiatives.
Mechanism of Action
Pharmacologic Class:
Retinoid
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Combination of Halobetasol Propionate and Tazarotene Lotion (Duobrii®) for Palmoplantar Plaque Type Psoriasis
Started Nov 2020
22 enrolled
Palmoplantar PsoriasisPlaque Psoriasis
Topical Tazarotene Vs Placebo In Hand-Foot-Skin Reactions
Started Dec 2019
8 enrolled
Solid TumorHand-Foot Skin Reaction (HFSR)
A Bioavailability Study of DFD-03 Compared to Tazorac® in Patients With Moderate Acne Vulgaris
Started Oct 2017
58 enrolled
Acne Vulgaris
A Study to Assess the Safety and Local Tolerability of DFD-03 (Tazarotene) Lotion, 0.1% Compared to Tazorac® Cream, 0.1% in the Topical Treatment of Acne Vulgaris
Started Aug 2017
155 enrolled
Acne Vulgaris
Absorption and Systematic Pharmacokinetics of IDP-123 Lotion in Comparison With Tazorac Cream
Started Jun 2016
48 enrolled
Acne
Worked on TAZORAC at Almirall? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.